Novartis AG (SWX:NOVN)
98.45
+0.05 (0.05%)
Sep 29, 2025, 10:52 AM CET
Novartis AG Revenue
Novartis AG had revenue of $14.84B USD in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.34
Revenue / Employee
$727.25K
Employees
75,883
Market Cap
190.49B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Lonza Group AG | 7.09B |
Galderma Group AG | 3.73B |
Alcon | 7.97B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.58B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 3 days ago - Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025 - GlobeNewsWire
- 3 days ago - DFIV, B, TD, NVS: Large Inflows Detected at ETF - Nasdaq
- 5 days ago - New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies - GlobeNewsWire
- 5 days ago - A Nobel Prize? How Big Pharma is trying to appease Trump - EURACTIV.com
- 6 days ago - Novartis Builds US Drug Reserves Against Potential Tariffs - Benzinga
- 7 days ago - Novartis (NVS) Boosts U.S. Pharmaceutical Inventory Amid Tariff Concerns - GuruFocus
- 7 days ago - Novartis (NVS) CEO Discusses Potential U.S. Price Reductions - GuruFocus
- 8 days ago - Novartis ramps up US stockpiles to shield against potential tariffs - Invezz